Patient and transplantation characteristics of allogeneic transplant recipients after nonmyeloablative conditioning
. | . | Invasive mold infection . | . | |
|---|---|---|---|---|
| Factors . | Total . | Yes . | No . | |
| Median patient age, y (range) | 53 (0-72) | 54 (25-67) | 53 (0-72) | |
| Sex, M/F | 107/56 | 15/10 | 92/46 | |
| Underlying diagnosis, n (%) | ||||
| Acute leukemia | 25 | 4 (16) | 21 (84) | |
| CML | 15 | 2 (13) | 13 (87) | |
| MDS/MPD | 18 | 3 (17) | 15 (83) | |
| Lymphoma/CLL/myeloma | 90 | 14 (16) | 76 (84) | |
| Other malignancy | 8 | 2 (25) | 6 (75) | |
| Nonmalignancy | 7 | 0 (0) | 7 (100) | |
| Disease risk, n (%)* | ||||
| High | 82 | 12 (15) | 70 (85) | |
| Low | 81 | 13 (16) | 68 (84) | |
| Prior transplant, n (%) | ||||
| Yes | 52 | 8 (15) | 44 (85) | |
| No | 111 | 17 (15) | 94 (85) | |
| Conditioning, n (%) | ||||
| 2 Gy TBI | 51 | 9 (18) | 42 (82) | |
| 2 Gy TBI + fludarabine | 112 | 16 (14) | 96 (86) | |
| Donor, n (%) | ||||
| HLA-matched related | 108 | 20 (19) | 88 (82) | |
| HLA-matched unrelated | 55 | 5 (9) | 50 (91) | |
| Stem cell source, n (%) | ||||
| PBSC | 148 | 24 (16) | 124 (84) | |
| Bone marrow | 15 | 1 (7) | 14 (93) | |
| Season of transplant, n (%) | ||||
| Winter | 35 | 2 (6) | 33 (94) | |
| Spring | 45 | 8 (18) | 37 (82) | |
| Summer | 49 | 10 (20) | 39 (80) | |
| Fall | 34 | 5 (15) | 29 (85) | |
| CMV risk group, n (%)† | ||||
| Low | 46 | 11 (24) | 35 (76) | |
| Intermediate | 27 | 3 (11) | 24 (89) | |
| High | 90 | 11 (12) | 79 (88) | |
. | . | Invasive mold infection . | . | |
|---|---|---|---|---|
| Factors . | Total . | Yes . | No . | |
| Median patient age, y (range) | 53 (0-72) | 54 (25-67) | 53 (0-72) | |
| Sex, M/F | 107/56 | 15/10 | 92/46 | |
| Underlying diagnosis, n (%) | ||||
| Acute leukemia | 25 | 4 (16) | 21 (84) | |
| CML | 15 | 2 (13) | 13 (87) | |
| MDS/MPD | 18 | 3 (17) | 15 (83) | |
| Lymphoma/CLL/myeloma | 90 | 14 (16) | 76 (84) | |
| Other malignancy | 8 | 2 (25) | 6 (75) | |
| Nonmalignancy | 7 | 0 (0) | 7 (100) | |
| Disease risk, n (%)* | ||||
| High | 82 | 12 (15) | 70 (85) | |
| Low | 81 | 13 (16) | 68 (84) | |
| Prior transplant, n (%) | ||||
| Yes | 52 | 8 (15) | 44 (85) | |
| No | 111 | 17 (15) | 94 (85) | |
| Conditioning, n (%) | ||||
| 2 Gy TBI | 51 | 9 (18) | 42 (82) | |
| 2 Gy TBI + fludarabine | 112 | 16 (14) | 96 (86) | |
| Donor, n (%) | ||||
| HLA-matched related | 108 | 20 (19) | 88 (82) | |
| HLA-matched unrelated | 55 | 5 (9) | 50 (91) | |
| Stem cell source, n (%) | ||||
| PBSC | 148 | 24 (16) | 124 (84) | |
| Bone marrow | 15 | 1 (7) | 14 (93) | |
| Season of transplant, n (%) | ||||
| Winter | 35 | 2 (6) | 33 (94) | |
| Spring | 45 | 8 (18) | 37 (82) | |
| Summer | 49 | 10 (20) | 39 (80) | |
| Fall | 34 | 5 (15) | 29 (85) | |
| CMV risk group, n (%)† | ||||
| Low | 46 | 11 (24) | 35 (76) | |
| Intermediate | 27 | 3 (11) | 24 (89) | |
| High | 90 | 11 (12) | 79 (88) | |
N = 163; with invasive mold infection: n = 25 patients (15%); without invasive mold infection: n = 138 patients (85%)
Patients were stratified based on underlying disease, as described previously15 : high-risk was defined as active or de novo or relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) (refractory anemia with excess of blasts or excess blasts in transformation), myeloproliferative disorder (MPD), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), multiple myeloma (MM) regardless of status, accelerated phase or blastic crisis of chronic myeloid leukemia (CML), or renal cell carcinoma; low-risk was defined as nonmalignant diseases including immune deficiency syndrome, any of the above diseases with unknown disease status or in remission except for MM, CML chronic phase, and MDS (refractory anemia with or without ringed sideroblasts)
Classification of the CMV risk group was based on pretransplantation CMV serostatus14 : CMV low-risk (donor and recipient serologically negative), CMV intermediate-risk (donor serologically positive and recipient negative), and CMV high-risk (recipient positive and donor negative or positive)